Since its discovery in the 1990s, "programmed cell death protein 1," or PD-1, has been regarded as a leading target in cancer treatments. A "checkpoint" receptor that often resides on the surface ...

Programmed cell death protein 1,” or PD-1, has been considered a key target in cancer therapies since its discovery in the ...

UC San Diego researchers reveal key differences in PD-1 checkpoint receptors between rodents and humans. Rodent PD-1 is ...

Cancer immunotherapy drugs called immune checkpoint inhibitors take the brakes off the body’s immune system, allowing it to ...

Researchers have discovered that mouse PD-1 is significantly weaker than human PD-1, calling into question their reliability ...

Evaxion Biotech has completed subject dosing in the Phase II trial of EVX-01, for the treatment of advanced melanoma.

About LM-299 LM-299 is an investigational bispecific antibody targeting both programmed cell death protein-1 (PD-1) and vascular endothelial growth factor (VEGF). This innovative therapeutic ...

This executive interview, sponsored by BeiGene, is with Jan-Henrik Terwey, Vice President, Medical Affairs Europe at BeiGene.

Studies of living participants and postmortem brains confirm that gene expansion is a promising target for HD prevention ...